Risk-Based Monitoring in Clinical Trials: A Cross-Functional Approach

Similar documents
Innovative Clinical Development Solutions

A statistics-based tool to inform riskbased monitoring approaches

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance

Risk Based Monitoring Initiative RISK-BASED MONITORING UPDATE - VOLUME 1

BEST PRACTICES GUIDE COMPLYING WITH THE ICH E6(R2) ADDENDUM

Risk-Based Monitoring - Prospective from CRO

Evolving Role of the Data Manager

Risk-Based Monitoring Improves Site Performance and Investigator Satisfaction

The Case for ICH E6(R2) Compliance Assessment

Less is the New More. Alternative models for Source Data Verification (SDV) Anna Wojciuk Clinical Data Manager Biometrics Department KCR

inventivhealthclinical.com The Goal: Reducing Uncertainty A Word on RBM

Approaches to Risk-Based Quality Management Quality by Design/Quality Systems

Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight

RBM Risk Based Monitoring GCP Training 12/SEP/2015. Gabor Kiss Synexus Hungary2015

Risk-Based Monitoring Update Volume IV

ICH E6 Guideline R 2 優良臨床試驗指引修改及增編附錄

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through four modules of information to

ICONik Patient Centric Monitoring The ICON s risk-based monitoring approach

Establishing our Trajectory: An Overview & Assessment of the Impact of ICH E6 R2 on Sites and Sponsors

For all the talk about how risk-based

Beyond SDV: Enabling Holistic, Strategic Risk-Based Monitoring

Risk-Based Monitoring Update Volume V

Risk Management in Clinical Trials in Today s ICH-GCP(R2) Framework

Risk-Based Monitoring Considerations in Rare Diseases Trials

Beyond SDV: Enabling Holistic, Strategic Risk-Based Monitoring

RISK-BASED MONITORING AND FRAUD DETECTION IN CLINICAL TRIALS USING JMP AND SAS

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

Integrating Trial Data Processes Across Functional Areas using Electronic Data Capture (EDC) Technology

EU Regulatory Perspective

Audit Program Background Definition Management Example Content Risk assessment approach

ELEMENTS OF A DATA MONITORING PLAN

Welcome to Module 2. In this module, we will be providing an overview of the TransCelerate Methodology process and toolkit, comparing off-site,

Exploration des données d essais cliniques en utilisant le standard CDISC

Innovations in Clinical

Phlexglobal Whitepaper

Central Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses

Monitoring Guidelines for Non-interventional Studies

Why Industry Collaboration Matters

The Role of the CRO in Effective Risk-Based Monitoring

Compliance and Quality Monitoring: What, Why, When, and How

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services

Approaches to targeted monitoring. and evidence (or not) to support them

Determining How to Make Data Review More Efficient by Utilizing Visualization Tools. Susan Doleman, Replimune Inc.

Adopting Site Quality Management to Optimize Risk-Based Monitoring

A Full-Service International CRO. Risk-based Monitoring: What it Needs to Be. Phil Doren, Ph.D., Global Vice President, Biometrics

Clinical Trial Performance Metrics

GLOBAL Trend and opportunities in drug development

Why Industry Collaborations Matter TransCelerate BioPharma, Inc.

Singapore Clinical Research Professional (CRP) /Clinical Research Coordinator Society (CRCS) Forum

CDER Perspective: Good Clinical Practice

Veeva 2015 Paperless TMF Survey: Annual CRO Report

Standard Operating Procedure

It s All About The RISK

Adaptive Risk Systems. Risk Assessment & Management Made Simple SM

Developing Strong Partnerships to Ensure Success With Global Medical Device Trials. 23-February-2017, OCT Burlingame

Sponsoring an IND? Ignorance is Not Always Blissful

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

CDISC Standards: Current and Future

Conducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency

ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc.

Statistical Monitoring Applied to Randomized Trials

RUNNING SMARTER TRIALS WITH DATA-DRIVEN

FDA Perspective on International Clinical Trials

CDER Perspective: Challenges in Clinical Trials and the Path Forward

TransCelerate Overview. Tozheg Roshankar

Clinical Trials & Regulatory

Anatomy of an FDA Audit Trigger Prevention and Process

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

Meeting sponsor s criteria : strategy to collaborate, engage and deliver

1 The Clinical Research Coordinator (CRC)... 1

Clinical trial databases are a crucial investment in clinical research. Part 4 - The "Life" of a Data Manager - Project Manager for the Database

BACKGROUND PURPOSE 9/24/2009 DATA AND SAFETY MONITORING

Good Clinical Practice (GCP) & Clinical Trial Registries

International Supply Chain: How are we handling globalisation? GCP oversight

What Could Go Wrong? ICH E6 R2, Investigative Sites and Risk Assessment Module 2 of a 4 Part Series

RISK-BASED MONITORING CURRENT PERSPECTIVES ON YOUR PEER-R EVIEWED GUIDE TO GLOBAL CLINICAL T RIAL S M A NAGEMENT. appliedclinicaltrialsonline.

INTRODUCING CLINIC AUTOMATION IN A PHASE I UNIT WITH END-TO-END E-SOURCE DATA PROCESSING

GCP Convergence Improves Transportability of Medical Device Clinical Data

STANDARD OPERATING PROCEDURE

Building Quality into Clinical Trials and Avoiding Common Pitfalls

KEY CONSIDERATIONS AND CHALLENGES OF EDC IN THE IMPLEMENTATION AND STATISTICS OF CLINICAL TRIALS

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Reducing the Time to Market with an eclinical System

Leading Provider of Technology-Enabled Solutions for Clinical Research

Enabling faster insights to improve clinical trial efficiency and quality

Trial Services. The allround trial specialist in cardiology Leading since cardialysis.com

Detailing key considerations and challenges of EDC to enable users to reap the cost, time and quality benefits

George Bernstein, Ph.D. Double Dragon Consulting

Adaptive Design for Medical Device Development

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor

GCP Basics - refresher

Getting Connected: The Benefits of a Unified Clinical Platform

Veeva 2015 Paperless TMF Survey: Annual Report

11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf

Trial Manager often = Trial Monitor Trial Team Impact on resources Build in efficiency and quality from beginning (pre-funding) Risk Assessment <->

Exploring the challenges, impacts and implications of risk-based monitoring

Transcription:

Risk-Based Monitoring in Clinical Trials: A Cross-Functional Approach Sharon Herbert, PhD. - Senior Medical Research Manager Tyson Rogers, MS - Senior Principal Medical Research Biostatistician

Clinical Trial Risks Inadequate human subject protections Untrained investigators / coordinators Inaccurate data Incorrectly performed study procedures Unreported adverse events Fabricated data Monitoring on-site is the traditional tool to detect these events Relatively effective, but costly and inefficient

What is Monitoring? Monitoring is a quality control tool for determining whether study activities are being carried out as planned, so that deficiencies can be identified and corrected 1. Traditional Monitoring: Monitoring a clinical trial by applying the same rules to each site / subject On-site & 100% SDV Risk-Based Monitoring (RBM): Monitoring a clinical trial by identifying risks to patient safety and data quality and then tailoring monitoring methods to address those risks. RBM may include: Centralized monitoring Targeted monitoring Reduced monitoring Remote monitoring 1 US FDA Guidance: Oversight of Clinical Investigations A Risk- Based Approach to Monitoring. August 2013

Risk-Based Monitoring Centralized Monitoring Reduced Monitoring Risk- Based Monitoring Targeted Monitoring Remote Monitoring An adaptive approach to monitoring that directs monitoring focus and activities to the evolving areas of greatest need, which have the most potential to impact subject safety and data quality.

Benefits of RBM over Traditional Monitoring? Not just: Reduced SDV and remote monitoring Reduction in overall cost Identify and prioritize risk Improve data quality and accuracy Mitigate risk Make data-driven decisions Improve patient safety

Transition to Risk-Based Monitoring is underway UK MRC/DH/MHRA Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products. October 2011. US FDA Guidance Oversight of Clinical Investigations A Risk-Based Approach to Monitoring. August 2013. European Medicines Agency Reflection Paper on Risk Based Quality Management in Clinical Trials; EMA/269011/2013. September 12, 2013. Japan Ministry of Health Basic Rules of the Risk-Based Approach to Monitoring Clinical Trials. July 2013 International Council for Harmonisation (ICH) Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). June 2015 (expected to take effect in 2016)

Key to Effective Risk-Based Monitoring? TECHNOLOGY??? CROSS-FUNCTIONAL APPROACH Assess study risks Tune mix of centralized, targeted, reduced, and remote monitoring Align site training with risk assessment Tailor key risk indicators (KRIs) to study Interpret metrics / analyses Effective action and resolution All of the above depend on an expert cross-functional team

Critical to have the right RBM partner Growing expectation from regulators that sponsors can: Provide documentation of a detailed risk assessment Provide clear rationale for choosing one monitoring strategy vs. another, that is documented Demonstrate appropriate oversight and follow-up Demonstrate the process is data-driven Provide an audit trail of actions and adjustments made during the course of a study

NAMSA s Risk-Based Monitoring Philosophy NAMSA takes a cognizant and thorough approach to creating and implementing global Risk-based Monitoring NAMSA applies an interactive approach to continually assess the data integrity and patient safety at the site and study levels NAMSA utilizes technology, cross-functional tools, intellect and resources to provide easyto-use reports for Risk-based Monitoring Focused, adaptive, customized, cross-functional approach: Upfront planning Ongoing data review Faster data-driven decisions Improved data quality

NAMSA Implementation of RBM Study Risk Profile (SRP) Risk- Based Monitoring Plan (RBMP) Centralized Data Monitoring Plan (CDMP) Periodic Review of RBM Site Metrics (Dashboard)

NAMSA s Risk-based Monitoring Approach Risk-based Planning Joint effort by Sponsor and a cross-functional team from Clinical, Data Management and Biostatistics Assess if the design and regulatory phase of the protocol are amenable to RBM Determine critical data and processes Develop study-level monitoring plans that incorporate risk assessment and mitigation Focus remote, centralized and on-site monitoring efforts on critical data and processes in order to achieve high quality compliant data with the most efficient utilization of resources

NAMSA s Risk-Based Monitoring Approach Data-driven statistical modeling of site-level risk based on rates of protocol deviations and AEs time to closure of monitoring action items and data queries subject withdrawal rates frequency of missed visits time to data entry coordinator engagement, PI oversight Utilize results to modify amount and type of site oversight as needed in order to preserve data and compliance integrity

NAMSA s Risk-Based Monitoring Approach Monitor Training Monitoring strategy & criteria that will drive adjustments to the strategy Activities performed onsite vs. remotely RBM-specific monitoring visit reports Communicating monitoring findings & following up on action items triggered by centralized monitoring Increased communication with sites Site Training Discuss RBM expectations during site qualification visits Source document transmission to support remote monitoring Electronic Trial Master File (etmf) Address concerns regarding increased burden on sites

Planning for Risk-Based Monitoring Develop Risk Profile and Identify Critical Data and Processes Determine Metrics for Effective Oversight Study Level Risk Perform Risk Assessment Relative to Critical Data and Processes Develop Monitoring and Mitigation Strategies to Address Risks

Implementation of Risk-Based Monitoring Implement Type and Level of Oversight From Monitoring Plan Continuously Review Metrics of Oversight Effectiveness Site Level Risk Update Study Level Risk Assessment as Necessary Mitigate Risk with Targeted Action (site follow- up, on- site monitoring, CAPA, etc.)

Study Oversight Metrics and Statistical Modeling Time to closure data queries and monitoring action items Rates of protocol deviations Time to data entry Subject withdrawal rates Frequency missed visits High/Low AE rates High/low procedure failure High/low within or between site variance Coordinator and PI engagement Site Level Risk Metrics of Oversight Effectiveness

Risk Metrics and Threshold Customization Identification of critical protocol deviations Key inclusion/exclusion criteria Correct device use Endpoint assessments Tolerable attrition / missing data rate Historical studies Sample size calculation assumptions Site performance expectations Time to data entry Response to queries Sensitivity level for adverse event rate variation

Risk Metrics Review Objective and Subjective Metrics Green/Yellow/Red Thresholds Adapt to Volume of Data Overall and Recent Time Window Risk Mitigation Action Tracking and Trending Dashboard + Drill-Down Detail Augmented by statistical data anomaly detection

Evidence for RBM & Centralized Statistical Monitoring TransCelerate Recent publication 1 on detection of fabricated data (3-10% prevalence) showed sensitivity ~80%, specificity ~70% Need to account for number of enrollments to determine site threshold ADAMON trial Compare traditional 100% SDV to riskdetermined monitoring strategy TEMPER study Evaluate metrics/thresholds by comparing triggered sites to matched untriggered sites on proportion with major finding NAMSA To conduct case study with 100% SDV performed after completion of RBM to evaluate any missed findings 1 Knepper D, et.al. Statistical Monitoring in Clinical Trials: Best Practices for Detecting Data Anomalies Suggestive of Fabrication or Misconduct. Drug Information Journal March 1, 2016 50: 144-154

Takeaways Risk-Based Monitoring is becoming the standard Ongoing evaluation of data integrity and study/site risk Tailored to study Sophisticated technology platform is not sufficient Requires expert cross-functional team integration into standard processes (with documentation)

Questions / Contact If you have any questions for our presenters, please email them to education@namsa.com.